Life sciences partner Katherine Wang (Shanghai) co-authored a Nov. 15 Law360 article that examines the China Food and Drug Administration’s (CFDA) final regulatory reform policy that encourages life sciences innovation in China.
The authors explain how the CFDA policies reflect the Chinese government’s unprecedented determination to accelerate drug and device approvals while deregulating the conduct of clinical research studies.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.